Identification of Mechanisms in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy

Next Previous
Trial Profile

Identification of Mechanisms in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Deferasirox (Primary) ; Deferoxamine (Primary)
  • Indications Anaemia; Aplastic anaemia; Myelodysplastic syndromes; Myelofibrosis
  • Focus Pharmacodynamics
  • Acronyms BIOFER12

    • Most Recent Events

    • 27 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
    • 27 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
    • 10 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top